The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: A randomized, double-blind, placebo-controlled study

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 28, Issue 7, 2006, Pages 447-450

  Huuhka, Kaija ^a   Riutta, A ^b   Haataja, R ^c   Ylitalo, P ^b   Leinonen, E ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

aMT6S; Antidepressants; CYP2C19; Cytochrome P450; Drug interaction; Inhibitors; Melatonin; Proton pump inhibitors; Urine

Indexed keywords

CYTOCHROME P450 2C19; MELATONIN;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG METABOLISM; ELDERLY CARE; FEMALE; HUMAN; MALE; RADIOIMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL; SLEEP PATTERN;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYL HYDROCARBON HYDROXYLASES; CITALOPRAM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MELATONIN; MENTAL DISORDERS; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; SEROTONIN UPTAKE INHIBITORS; SLEEP DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33749991562     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2006.28.7.1003545     Document Type: Article

References (35)

1. Brzezinski, A. Melatonin in humans. N Engl J Med 1997, 336: 186-95.
2. Claustrat, B., Brun, J., Chazot, G. The basic physiology and pathophysiology of melatonin. Sleep Med 2005, 9: 11-24.
3. DeMuro, R.L., Nafziger, A.N., Blask, D.E., Menhinick, A.M., Bertino, J.S., Jr. The absolute bioavailability of oral melatonin. J Clin Pharmacol 2000, 40: 781-4.
4. Härtter, S., Wang, X., Weigmann, H. et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol 2001, 21: 167-74.
5. Leone, A.M., Francis, P.L., Silman, R.E. The isolation, purification and characterization of the principal urinary metabolites of melatonin. J Pineal Res 1987, 4: 253-66.
6. Kveder, S., McIsaac, W.M. The metabolism of melatonin (N-acetyl-5-methoxytryptamine) and 5-methoxytryptamine. J Biol Chem 1961, 236: 3214-20.
7. Young, I.M., Leone, R.M., Francis, P., Stovell, P., Silman, R.E. Melatonin is metabolized to N-acetyl serotonin and 6-hydroxy-melatonin in man. J Clin Endocrinol Metab 1985, 60: 114-9.
8. Facciola, G., Hidestrand, M., von Bahr, C., Tybring, G. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol 2001, 56: 881-8.
9. Skene, D.J., Papagiannidou, E., Hashemi, E. et al. Contribution of CYP1A2 in the hepatic metabolism of melatonin: Studies with isolated microsomal preparations and liver slices. J Pineal Res 2001, 31: 333-42.
10. Ma, X., Idle, J.R., Krausz, K.W., Gonzalez, F.J. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos 2005, 33: 489-94.
11. Hiemke, C., Härtter, S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000, 85: 11-28.
12. Rochat, B., Amey, M., Gillet, M., Meyer, U.A., Baumann, P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997, 7: 1-10.
13. Liu, K.H., Kim, M.J., Moon, Y.S. et al. Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. Xenobiotica 2005, 35: 27-38.
14. Li, X.Q., Andersson, T.B., Ahlström, M., Weidolf, L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomepratzole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004, 32: 821-7.
15. Ko, J.-W., Sukhova, N., Thacker, D., Chen, P., Flockhart, D.A. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997, 25: 853-62.
16. Brøsen, K., Skjelbo, E., Rasmussen, B.B., Poulsen, H.E., Loft, S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993, 24: 1211-4.
17. Yao, C., Kunze, K.L., Trager, W.F., Kharasch, E.D., Levy, R.H. Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metab Dispos 2003, 31: 565-71.
18. Härtter, S.; Grözinger, M., Weigmann, H., Röschke, J., Hiemke, C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 2000, 67: 1-6.
19. von Bahr, C., Ursing, C., Yasui, N., Tybring, G., Bertilsson, L., Rojdmark, S. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - An indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol 2000, 56: 123-7.
20. Haimov, I., Lavie, P., Laudon, M., Herer, P., Vigder, C., Zisapel, N. Melatonin replacement therapy of elderly insomniacs. Sleep 1995, 18: 598-603.
21. Garfinkel, D., Laudon, M., Nof, D., Zisapel, N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995, 346: 541-4.
22. Folstein, M.F., Folstein, S.E., McHugh, P.R. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 14: 189-98.
23. Rodbard, D. Statistical control and routine data processing for radioimmunoassays and immunoradiometric assays. Clin Chem 1974, 20: 1255-70.
24. Arendt, J., Bojkowski, C., Franey, C., Wright, J., Marks, V. Immunoassay of 6-hydroxymelatonin sulphate in human plasma and urine: Abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Met 1985, 60: 1166-73.
25. Markey, S.P., Higa, S., Shih, M., Danforth, D.N., Tamarkin, L. The correlation between human plasma melatonin levels and urinary 6-hydroxymelatonin excretion. Clin Chim Acta 1985, 150: 221-5.
26. Nowak, R., McMillen, I.C., Redman, J., Short, R.V. The correlation between serum and salivary melatonin and urinary 6-hydroxymelatonin sulphate excretion rates: Two non-invasive techniques for monitoring human circadian rhythmicity. Clin Endocrinol 1987, 27: 445-52.
27. Bojkowski, C.J., Arendt, J., Shih, M.C., Markey, S.P. Melatonin secretion in humans assessed by measuring its metabolite, 6-sulfatoxymelatonin. Clin Chem 1987, 33: 1343-8.
28. Baskett, J.J., Cockrem, J.F., Antunovich, T.A. Sulphatoxymelatonin excretion in older people: Relationship to plasma melatonin and renal function. J Pineal Res 1998, 24: 58-61.
29. Crasson, M., Kjiri, S., Colin, A. et al. Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocrinology 2004, 29: 1-12.
30. Leger, D., Laudon, M., Zisapel, N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004, 116: 91-5.
31. Kovacs, J., Brodner, W., Kirchlechner, V., Arif, T., Waldhauser, F. Measurement of urinary melatonin: A useful tool for monitoring serum melatonin after its oral administration. J Clin Endocrinol Metab 2000, 85: 666-70.
32. Wetterberg, L., Bergiannaki, J.D., Paparrigopoulos, T. et al. Normative melatonin excretion: A multinational study. Psychoendocrinology 1999, 24: 209-26.
33. Kayumov, L., Brown, G., Jindal, R., Buttoo, K., Shapiro, C.M. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosomatic Med 2001, 63: 40-8.
34. Xie, H.G., Stein, C.M., Kim, R.B., Wilkinson, G.R., Flockhart, D.A., Wood, A.J. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999, 9: 539-49.
35. Baskett, J.J., Broad, J.B., Wood, P.C. et al. Does melatonin improve sleep in older people? A randomised crossover trial. Age Ageing 2003, 32: 164-70.